Literature DB >> 28588316

Renin-angiotensin blockade in atrial fibrillation: where are we now?

F Shahid1, G Y H Lip1,2, E Shantsila1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28588316     DOI： 10.1038/jhh.2017.6

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN： 0950-9240            Impact factor:   3.012


× No keyword cloud information.
  19 in total

1.  Left ventricular fibrosis in atrial fibrillation.

Authors:  Eduard Shantsila; Alena Shantsila; Andrew D Blann; Gregory Y H Lip
Journal:  Am J Cardiol       Date:  2013-01-17       Impact factor: 2.778

2.  Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.

Authors:  Paul Milliez; Xavier Girerd; Pierre-François Plouin; Jacques Blacher; Michel E Safar; Jean-Jacques Mourad
Journal:  J Am Coll Cardiol       Date:  2005-04-19       Impact factor: 24.094

3.  Preventive effect of renin-angiotensin system inhibitors on new-onset atrial fibrillation in hypertensive patients: a propensity score matching analysis.

Authors:  T Horio; M Akiyama; Y Iwashima; F Yoshihara; S Nakamura; T Tokudome; M Okutsu; H Tanaka; I Komatsubara; N Okimoto; S Kamakura; Y Kawano
Journal:  J Hum Hypertens       Date:  2016-12-29       Impact factor: 3.012

4.  Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.

Authors:  Gregory Y H Lip; Andreas Clemens; Herbert Noack; Jorge Ferreira; Stuart J Connolly; Salim Yusuf
Journal:  Thromb Haemost       Date:  2013-12-11       Impact factor: 5.249

5.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

6.  Long-term effect of antihypertensive drugs on the risk of new-onset atrial fibrillation: a longitudinal cohort study.

Authors:  Gwo-Ping Jong; Hung-Yi Chen; Shu-Yi Li; Yi-sheng Liou
Journal:  Hypertens Res       Date:  2014-06-26       Impact factor: 3.872

7.  Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation.

Authors:  Philippe L L'Allier; Anique Ducharme; Pierre-Frédéric Keller; Holly Yu; Marie-Claude Guertin; Jean-Claude Tardif
Journal:  J Am Coll Cardiol       Date:  2004-07-07       Impact factor: 24.094

8.  Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.

Authors:  Roland E Schmieder; Sverre E Kjeldsen; Stevo Julius; Gordon T McInnes; Alberto Zanchetti; Tsushung A Hua
Journal:  J Hypertens       Date:  2008-03       Impact factor: 4.844

9.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Authors:  S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

10.  TGF-β1, released by myofibroblasts, differentially regulates transcription and function of sodium and potassium channels in adult rat ventricular myocytes.

Authors:  Kuljeet Kaur; Manuel Zarzoso; Daniela Ponce-Balbuena; Guadalupe Guerrero-Serna; Luqia Hou; Hassan Musa; José Jalife
Journal:  PLoS One       Date:  2013-02-05       Impact factor: 3.240
View more
  2 in total

1.  Pulse pressure, arterial stiffening, and the efficacy of renin-angiotensin system inhibitor combinations.

Authors:  Kalyani B Sonawane; Ashish A Deshmukh; Mark S Segal
Journal:  J Hum Hypertens       Date:  2017-12-11       Impact factor: 3.012

Review 2.  Genetics and Epigenetics of Atrial Fibrillation.

Authors:  Estefanía Lozano-Velasco; Diego Franco; Amelia Aranega; Houria Daimi
Journal:  Int J Mol Sci       Date:  2020-08-10       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.